Cutaneous Melanoma Detection and Management
Research Guide

The HAM10000 dataset is a large collection of 10,000 multi-source dermatoscopic images of common pigmented skin lesions. Philipp Tschandl et al. (2018) released it to address limitations in dataset size and diversity for training neural networks in automated diagnosis of skin lesions including melanoma. It supports development of deep learning models for pigmented skin cancer recognition.

Vemurafenib improves rates of overall and progression-free survival in patients with previously untreated melanoma harboring the BRAF V600E mutation. Paul B. Chapman et al. (2011) demonstrated this in the BRIM-3 trial funded by Hoffmann-La Roche (NCT01006980). The targeted therapy addresses mutated BRAF in metastatic cases.

The 2009 AJCC melanoma staging was revised based on multivariate analysis of 30,946 patients with stages I, II, and III cutaneous melanoma from an expanded database. Charles M. Balch et al. (2009) proposed changes to enhance prognostic accuracy. It remains a standard for tumor staging and classification.

Sentinel lymph node biopsy identifies the initial lymphatic route of metastases in early-stage melanoma patients. Donald L. Morton (1992) detailed intraoperative lymphatic mapping techniques to target regional nodes accurately. It helps avoid routine lymphadenectomy in node-negative cases.

Deep neural networks achieve dermatologist-level classification of skin cancer, including melanoma, by training on large image datasets. Andre Esteva et al. (2017) demonstrated this performance in their Nature paper with 12,836 citations. The approach supports automated dermoscopy analysis.

Genomic classification identifies molecular subtypes of cutaneous melanoma through comprehensive profiling. Rehan Akbani et al. (2015) detailed this in Cell, linking alterations to tumor behavior. It informs targeted therapies like BRAF inhibitors.